Boston Scientific Corporation BSX
Boston Scientific Corporation (NYSE: BSX) is a drug developer. Its lead program is marketed. Its next catalyst on record is Penumbra acquisition: Acquisition closing (pending FTC review) (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Penumbra acquisition — Acquisition closing (pending FTC review) (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Recent results and decisions
- Oct 28, 2026started Boston Scientific commenced enrollment in the Elite AF clinical trial to evaluate the next-generation WATCHMAN Elite™ device in patients with non-valvular atrial fibrillation.
Commenced enrollment in the Elite AF clinical trial to evaluate the safety and effectiveness of the next-generation WATCHMAN Elite™ Left Atrial Appendage Closure Device in patients with non-valvular atrial fibrillation.
Filing - Oct 28, 2026approval Boston Scientific received FDA 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem including Navigator™ Flex Ureteral Access Sheath Set and LithoVue™ Elite Ureteroscope.
Received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the Navigator™ Flex Ureteral Access Sheath Set, designed to enable the use of suction to remove kidney stone debris, and the LithoVue™ Elite Single-Use Digital
Filing - Oct 28, 2026approval Boston Scientific received FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat severely calcified peripheral artery disease.
Received U.S. FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.